newsfilter
← Latest News
GlobeNewswire·

Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial

- Durable Clinical Benefit Observed Beyond a Year on Treatment in Heavily Pre-Treated Patients Boston (September 16, 2024) — Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a clinical-stage